Cardiology

Top Story

FDA approves evolocumab as LDL-lowering therapy in certain patients

August 27, 2015

The FDA has approved evolocumab, a PCSK9 inhibitor, for lowering LDL in adults with heterozygous or homozygous familial hypercholesterolemia or clinical atherosclerotic CVD, according to a press release from the agency.

Evolocumab (Repatha, Amgen) is intended for use in addition to diet and maximally tolerated statin therapy in patients with heterozygous familial hypercholesterolemia (HeFH) or atherosclerotic CVD, and in addition to diet and other LDL-lowering therapies for patients with homozygous familial hypercholesterolemia (HoFH), according to an Amgen press release.

In the Journals

FFR accurately diagnoses flow-limiting CAD in patients with non-STEMI

August 27, 2015
Fractional flow reserve demonstrated high diagnostic accuracy for flow limitation at the lesion level compared with stress perfusion cardiac magnetic resonance at 3 T…
In the Journals

Overall global health improving, years lived with disability rising

August 27, 2015
Around the world, the average life expectancy increased by more than 6 years between 1990 and 2013; however, individuals are spending more years than ever living with…
Koji Miyamoto, MD, PhD In the Journals

Renal function decline common in patients with AF prescribed anticoagulants

August 27, 2015
Deterioration of renal function, and an increase in related adverse events, may not be unusual in patients with nonvalvular atrial fibrillation prescribed nonvitamin K…
In the Journals

DANTE: Discontinuing antihypertensive medications did not improve cognitive function in elderly patients

August 27, 2015
Discontinuing antihypertensive medications did not improve cognitive, psychological or general daily functioning in elderly patients with mild cognitive defects…
More News Headlines »
CME
PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

PCI in ACS: Deciding Among Clopidogrel, Prasugrel, or Ticagrelor

This activity is supported by an educational grant from Daiichi Sankyo, Inc. and Lilly USA, LLC

It is estimated that in the United States, each year, over 780,000 persons will experience an acute coronary syndrome…
More »
Video
VIDEO: Prenatal intervention may improve neurodevelopmental outcomes from congenital heart defects

VIDEO: Prenatal intervention may improve neurodevelopmental outcomes from congenital heart defects

July 23, 2015
PHILADELPHIA — In this video, J. William Gaynor, MD, a cardiac surgeon at the Children's Hospital of…
More »
CME
Highlights from Lipid Forum 2015™: Focus on Hypertriglyceridemia

Highlights from Lipid Forum 2015®: Focus on Hypertriglyceridemia

This activity is supported by an educational grant from AstraZeneca.

Hypertriglyceridemia is a highly prevalent yet modifiable risk factor for atherosclerotic disease, pancreatitis, and…
More »
morganatic-roan
morganatic-roan